Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Garivulimab |
| Trade Name | |
| Synonyms | BGBA333|BGB A333|BGB-A333 |
| Drug Descriptions |
Garivulimab (BGB-A333) is a monoclonal antibody that targets CD274 (PD-L1), potentially resulting in anti-tumor activity (Annals of Oncology 31 (2020): S468-S469). |
| DrugClasses | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 133 |
| CAS Registry Number | 2342597-81-1 |
| NCIT ID | C155654 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Garivulimab | Garivulimab | 0 | 0 |
| Garivulimab + Tislelizumab | Garivulimab Tislelizumab | 0 | 0 |